Header

UZH-Logo

Maintenance Infos

VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes


Calin, Manuela; Stan, Daniela; Schlesinger, Martin; Simion, Viorel; Deleanu, M; Constantinescu, C; Gan, AM; Pirvulescu, M; Butoi, E; Manduteanu, I; Bota, M; Enachescu, M; Borsig, Lubor; Bendas, Gerd; Simionescu, Maya (2015). VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes. European Journal of Pharmaceutics and Biopharmaceutics, 89:18-29.

Abstract

Chemokines are critically involved in the development of chronic inflammatory-associated diseases such as atherosclerosis. We hypothesised that targeted delivery of compounds to the surface of activated endothelial cells (EC) interferes with chemokine/receptor interaction and thereby efficiently blocks inflammation. We developed PEGylated target-sensitive liposomes (TSL) encapsulating a CCR2 antagonist (Teijin compound 1) coupled with a specific peptide recognized by endothelial VCAM-1 (Vp-TSL-Tj). TSL were characterized for size (by dynamic light scattering), the amount of peptide coupled at the surface of liposomes and Teijin release (by HPLC). We report that Vp-TSL-Tj binds specifically to activated EC in vitro and in vivo, release the entrapped Teijin and prevent the transmigration of monocytes through activated EC. This is the first evidence that nanocarriers transporting and releasing chemokine inhibitors at specific pathological sites reduce the chemokine-dependent inflammatory process.

Abstract

Chemokines are critically involved in the development of chronic inflammatory-associated diseases such as atherosclerosis. We hypothesised that targeted delivery of compounds to the surface of activated endothelial cells (EC) interferes with chemokine/receptor interaction and thereby efficiently blocks inflammation. We developed PEGylated target-sensitive liposomes (TSL) encapsulating a CCR2 antagonist (Teijin compound 1) coupled with a specific peptide recognized by endothelial VCAM-1 (Vp-TSL-Tj). TSL were characterized for size (by dynamic light scattering), the amount of peptide coupled at the surface of liposomes and Teijin release (by HPLC). We report that Vp-TSL-Tj binds specifically to activated EC in vitro and in vivo, release the entrapped Teijin and prevent the transmigration of monocytes through activated EC. This is the first evidence that nanocarriers transporting and releasing chemokine inhibitors at specific pathological sites reduce the chemokine-dependent inflammatory process.

Statistics

Citations

Dimensions.ai Metrics
10 citations in Web of Science®
11 citations in Scopus®
8 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

33 downloads since deposited on 07 Jan 2016
22 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:10 January 2015
Deposited On:07 Jan 2016 11:47
Last Modified:18 Apr 2018 11:47
Publisher:Elsevier
ISSN:0939-6411
Funders:SNSF
OA Status:Green
Publisher DOI:https://doi.org/10.1016/j.ejpb.2014.11.016
PubMed ID:25438248
Project Information:
  • : FunderSNSF
  • : Grant ID
  • : Project TitleSNSF

Download

Download PDF  'VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 194kB
View at publisher